Baupost Group LLC MA Has $95.54 Million Stock Position in Solventum Co. (NYSE:SOLV)

Baupost Group LLC MA lowered its stake in shares of Solventum Co. (NYSE:SOLV - Free Report) by 20.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,446,300 shares of the company's stock after selling 373,700 shares during the period. Solventum makes up 2.8% of Baupost Group LLC MA's portfolio, making the stock its 14th biggest position. Baupost Group LLC MA owned approximately 0.84% of Solventum worth $95,543,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of SOLV. Modus Advisors LLC bought a new position in Solventum in the fourth quarter valued at approximately $25,000. Stonebridge Financial Group LLC bought a new position in shares of Solventum in the fourth quarter valued at $26,000. Crews Bank & Trust bought a new stake in Solventum during the fourth quarter worth $32,000. Synergy Asset Management LLC acquired a new stake in Solventum in the fourth quarter valued at $35,000. Finally, Spire Wealth Management bought a new position in shares of Solventum in the 4th quarter valued at about $37,000.

Analyst Upgrades and Downgrades

SOLV has been the topic of a number of research analyst reports. The Goldman Sachs Group upped their target price on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a report on Monday, March 3rd. Piper Sandler lifted their target price on Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a research note on Friday, February 28th. Bank of America boosted their price target on Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a research note on Wednesday, February 26th. Morgan Stanley raised their target price on shares of Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th. Finally, Mizuho lifted their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research note on Monday, March 3rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, Solventum currently has a consensus rating of "Hold" and an average price target of $79.86.

Solventum Trading Up 0.8 %

Shares of SOLV stock traded up $0.56 during mid-day trading on Friday, reaching $66.23. 910,263 shares of the stock traded hands, compared to its average volume of 1,322,930. The stock's fifty day simple moving average is $73.41 and its two-hundred day simple moving average is $71.61. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $85.92. The company has a market cap of $11.46 billion and a price-to-earnings ratio of 24.08.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.